Drug
Netarsudil clinical trials
Also written Rhopressa.
- studies test it
- 32
- open now
- 4
- in phase 3
- 11
- first study started
- 2012
Keep track of what changes. Save the netarsudil studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 3
- Phase 2
- 12
- Phase 3
- 11
- Phase 4
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 13
Aerie Pharmaceuticals (16) · Massachusetts Eye and Ear Infirmary (3) · Price Vision Group (2) · East Coast Institute for Research (1) · University Hospital Dubrava (1) · Alcon Research (1) · Westlake Eye Specialists (1) · Cornea Research Foundation of America (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses netarsudil is read from its arms, and is right about nine times in ten.
Testing it · 32
- Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal DetachmentRecruitingPhase 1/2Massachusetts Eye and Ear InfirmaryNCT06033703Written as Netarsudil Ophthalmic
- Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma PatientsRecruitingPhase 4Brett KingNCT07847073Written as Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]
- Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular HypertensionRecruitingPhase 4Indiana UniversityNCT07588152Written as Netarsudil Ophthalmic Solution (Rhopressa)
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension PatientsRecruitingPhase 4Mayo ClinicNCT07325240Written as Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
- The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)CompletedPhase 2/3University Hospital DubravaNCT06960629Written as Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
- Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLTActive, not recruitingPhase 4East Coast Institute for ResearchNCT06865144Written as Netarsudil ophthalmic solution 0.02%
- Reformulated PG324 Ophthalmic Solution for Intraocular Pressure ReductionCompletedPhase 3Alcon ResearchNCT07082816Written as Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution
- Effect of Netarsudil vs Brimonidine in NTG Patients on LatanoprostCompletedPhase 4Westlake Eye SpecialistsNCT06449352Written as Netarsudil
- A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVRStatus unknownPhase 2/3Wills EyeNCT05660447Written as Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]
- Rocklatan® EvaluationCompletedPhase 4Aerie PharmaceuticalsNCT05283395Written as Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
- Netarsudil Use After Descemtorhexis Without Endothelial KeratoplastyCompletedEarly Phase 1Massachusetts Eye and Ear InfirmaryNCT04752020Written as Netarsudil Ophthalmic
- Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy VolunteersCompletedPhase 1Aerie PharmaceuticalsNCT01997879Written as AR-13324 Ophthalmic Solution, 0.02%
- Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedPhase 3Aerie PharmaceuticalsNCT04620135Written as Netarsudil ophthalmic solution 0.02%
- Trial of Netarsudil for Acceleration of Corneal Endothelial RestorationTerminatedPhase 2/3Price Vision GroupNCT03971357Written as Netarsudil
- A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal DystrophyCompletedPhase 2Aerie PharmaceuticalsNCT04498169Written as Netarsudil Ophthalmic
- Rhopressa for Corneal Edema Associated With Fuchs DystrophyCompletedPhase 2/3Price Vision GroupNCT04051463Written as Netarsudil Ophthalmic Solution
- Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension GlaucomaStatus unknownPhase 4Salus UniversityNCT04981886Written as Netarsudil Ophthalmic
- Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure ElevationCompletedPhase 3Cornea Research Foundation of AmericaNCT03248037Written as Netarsudil
- Netarsudil Use After Descemetorhexis Without Endothelial KeratoplastyCompletedEarly Phase 1Massachusetts Eye and Ear InfirmaryNCT04057053Written as Netarsudil 0.02% Ophthalmic Solution
- Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in JapanCompletedPhase 2Aerie PharmaceuticalsNCT03844945Written as Netarsudil Ophthalmic Solution 0.01%
See all 32 studies that test netarsudil →
As the comparator · 5 — what is tested is compared with netarsudil
- Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular HypertensionCompletedPhase 2Laboratoires TheaNCT06394973Written as Rhopressa®
- Next Generation RocklatanCompletedPhase 2Alcon ResearchNCT06441643Written as Netarsudil 0.02% Ophthalmic Solution
- Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionCompletedPhase 3Aerie PharmaceuticalsNCT02558400Written as Netarsudil (AR-13324) Ophthalmic Solution 0.02%
- Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular PressureCompletedPhase 2Aerie PharmaceuticalsNCT02057575Written as Netarsudil (AR-13324) Ophthalmic Solution 0.02%
- Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular HypertensionCompletedPhase 3Aerie PharmaceuticalsNCT02674854Written as Netarsudil (AR-13324) ophthalmic solution 0.02%
Codes
What other systems call netarsudil · ClinicalTrials.gg INT000366
- MeSH (NLM) C000603944netarsudilOne source NLM
- UNII (FDA) W6I5QDT7QINETARSUDILConfirmed FDA, NLM, Wikidata
- RxNorm 1992864One source FDA
- Wikidata Q27292390netarsudilConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170213NetarsudilOne source FDA
- DrugBank DB13931One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000603944 | netarsudil | One source NLM |
| UNII (FDA) | W6I5QDT7QI | NETARSUDIL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1992864 | — | One source FDA |
| Wikidata | Q27292390 | netarsudil | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170213 | Netarsudil | One source FDA |
| DrugBank | DB13931 | — | One source Wikidata |
Also registered as netarsudil mesylate (UNII VL756B1K0U · RxNorm 1992863).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.